Pfizer Announces Results Of Early Tenders And Consents In Exchange Offers

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (“Pfizer”) (NYSE:PFE) announced today that, as of 5:00 p.m., New York City time, on September 17, 2015 (the “Early Consent Date”), the aggregate principal amounts of each series of notes listed in the table below (collectively, the “Hospira Notes”) issued by Hospira, Inc., a recently acquired subsidiary of Pfizer, had been validly tendered and not validly withdrawn in connection with Pfizer’s previously announced offers to exchange any and all validly tendered and accepted Hospira Notes for new notes to be issued by Pfizer (collectively, the “Pfizer Notes”), and the related solicitations of consents to amend the indenture governing the Hospira Notes and the Hospira Notes (together, the “Exchange Offers”). A Registration Statement on Form S-4 (File No. 333-206758) (the “Registration Statement”) relating to the issuance of the Pfizer Notes was filed with the Securities and Exchange Commission (“SEC”) on September 3, 2015, as amended by Amendment No. 1 to the Registration Statement, filed with the SEC on September 16, 2015, but has not yet been declared effective.

Help employers find you! Check out all the jobs and post your resume.